Vanderbilt Vaccine Center

The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center. Read More

Researchers led by James Crowe Jr. are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. The hope is that the antibodies — like heat-seeking missiles — would seek out and destroy the viruses before they can wreak havoc in the body. Read More

Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus. Read More

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members. Read More

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses. Read More

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus. Read More

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week. Read More

K. Dane Wittrup, PhD, a pioneer in protein engineering technologies who has helped accelerate development of antibody therapies for cancer, will deliver the next Flexner Discovery Lecture on Thursday, March 22. Read More

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design. Read More

The lasting impact of the historic partnership between the federal government and America's research universities is the topic of this week's column from Chancellor Nicholas S. Zeppos. Read More

From Vanderbilt Magazine: James Crowe, director of the Vanderbilt Vaccine Center, hopes to create a universal flu vaccine--permanently eliminating the problem of ineffective or under-effective annual flu shots. Read More

A renowned microbiologist and Ann Scott Carell Professor, Crowe is leading efforts to decipher the human immunome, a vast set of genes and molecular structures critical to fighting disease. Understanding those mechanics could lead to the development of a universal flu vaccine. No guessing required. Read More

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika. Read More

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI). Read More

Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world. Read More

The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system. Read More

The Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center invite you to attend the 2017 Symposium on Modeling Immunity April 27. The event will focus on modeling and designing antibodies. Read More

The 2017 Vanderbilt Symposium on Modeling Immunity will be held from 1 to 4:30 p.m. Thursday, April 27, in room 1220 MRB III. Read More

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics. Read More

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide. Read More